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Abstract  
Patients receiving oral anticoagulant (OAC) therapy for stroke prevention in atrial fibrillation (AF) and 
prevention of venous thromboembolism (VTE) face an increased risk of bleeding with OAC treatment. 
Clinicians need to weigh-up the benefits of OAC treatment against the risk of bleeding. To help formalise 
bleeding risk assessment, various bleeding risk scores have been developed to help predict the risk of 
bleeding in AF and VTE patients receiving anticoagulant therapy. This review summarises the literature 
involving original studies deriving bleeding risk scores and validation studies of these scores for stroke 
prevention in AF and treatment/prevention of VTE. To date, there are 10 bleeding risk scores, 6 for use if 
AF populations, three in VTE cohorts and 1 for mixed indications; they differ markedly in the number of, 
and risk factors for bleeding, and complexity. In conclusion, many clinical prediction tools to assess 
bleeding risk prior to starting OAC for either stroke prevention in AF or treatment of VTE are available and 
should be used in clinical practice to identify and manage modifiable risk factors. 
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Oral anticoagulants (OAC), including vitamin K antagonists (VKAs) and non-VKA oral anticoagulants 
(NOACs) are recommended to prevent thromboembolic events in patients with atrial fibrillation (AF) and 
for primary and secondary prevention of venous thromboembolism (VTE). However, OAC use is 
associated with an increased risk of major bleeding, the most serious of which is intracranial hemorrhage 
(ICH).
1
 In clinical practice, estimating the bleeding risk of an individual patient is beneficial before starting 
an anticoagulant,
2
 particularly to identify and manage modifiable bleeding risk factors.  In addition bleeding 
risk assessment could help to identify those at higher bleeding risk for whom additional measures, such as 
more regular follow-up visits and good International Normalised Ratio (INR) management (for those on 
VKAs), providing information and/or practical measures to reduce the falls risk, and informing patients 
about high-risk activities
1
 to reduce bleeding risk
3
 could be implemented. Bleeding risk scoring systems 
have been developed for use in AF and VTE patients to estimate bleeding risk and to help aid treatment 
decisions. These scores have been tested and validated worldwide in many cohorts of AF
4-9
 and VTE
10-12
 to 
support physicians in assessing bleeding risks.
13
 More recently, the European Society of Cardiology (ESC) 
Guidelines on the management of AF summarised bleeding risks (into modifiable, potentially modifiable, 
non-modifiable and biomarker-based) and encouraged prompt attention to correct modifiable bleeding 
risks.
14
 This review summarises the original derivation and validation studies of these bleeding risk scores 
for stroke prevention in AF and treatment/prevention of VTE. 
 
Methods 
A literature search was performed in EMBASE (1974 to April 21 2016), EMBASE Classic (1947 
to 1973), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) (1946 to 
present). The search strategy included keywords and MeSH terms relating to bleeding risk score, major 
bleeding, bleeding, AF, VTE, warfarin, and oral anticoagulant individually and in combination. Primary 
published research articles on prospective or retrospective studies where bleeding risk scores were derived 
4 
 
and validated were included. Studies that did not provide comparative outcomes, information on follow up 
time, or were not published in the English language were excluded. A manual search of the reference lists 
was also performed for studies that were not retrieved by the database searches.   
To date, 6 bleeding risk scores are available for use in AF populations,
4-9
 3 in VTE populations
10-12
 
and 1 in a mixed indication population.
15
 Tables 1 to 4 summarises the main published prospective or 
retrospective studies where bleeding risk scores in patients with AF and VTE who are treated with warfarin 
were derived and/or validated.  
Many different risk factors for bleeding are included in the various bleeding scores (Table 1), with 
the number of risk factors included ranging from three
4,12
 to 12.
8
 All bleeding scores
4-12,15
 included age, 
utilising different age ranges and cut-offs (ranging from > 50 years old to > 85 years old) to indicate greater 
risk of bleeding; four scores included age ≥75 years.5,6,8,11 After age, the most common bleeding risk factors 
included in the scores were as follows: (i) previous/remote bleeding (reported in 8 scores),
4-9,11,15
 (ii) renal 
disease (included in 7 scores),
5-8,10,11,15
 (iii) anemia (in 6 scores),
5,6,8,9,11,15
 malignancy (in 4 scores);
8,10-12
 
liver disease,
7,8,10
 hypertension,
6-8
 stroke,
7,8,15
 combined antiplatelet therapy
5,7,9
 and alcohol excess,
7-9
 (all 
included in 3 scores), while two scores included diabetes mellitus,
9,15
 reduced platelet count
8,10
 and female 
sex.
9,12
 
Other risk factors included biomarkers (high-sensitivity troponin, cTnT-hs and growth 
differentiation factor-15, GDF-15), recent bleed, myocardial infarction, labile INR, excessive falls risk, 
genetic factors, active gastro-duodenal ulcer, Intensive Care Unit/Coronary Care Unit (ICU/CCU) 
admission, central venous catheter, rheumatic disease, male sex and clinically overt pulmonary embolism. 
Seven
5,6,8-11,15
 out of 10 studies reported patients with a history or diagnosis of cancer, as malignancy is 
associated with increased risk of bleeding;
12,16
 about 2.5%-30% had a history/diagnosis of cancer  (Table 
2). All 3
10-12
 bleeding scores for VTE patients include history or current diagnosis of cancer in their 
bleeding score, as cancer is shown to increase the risk of thromboembolism.
17,18
 Interestingly the ORBIT
 5
 
5 
 
score and the score developed by Ruiz-Gimenez et al
11
 found almost 60% of their population had anemia, 
also a known risk factor for bleeding. In most bleeding scores
4-7,9
 for AF, hypertension was the most 
prevalent co-morbidity followed by congestive heart failure and diabetes.  
Clinically overt PE was included as a risk factor for bleeding only in the VTE bleeding score by 
Ruiz-Gimenez et al.
11
 The aim of the other 2 VTE scores
10,12
 was to develop a score with the ability to 
distinguish patients at low, mild or high risk of major bleeding during the first 90 days of OAC therapy. 
Kuijer et al
12
 constructed the simplest bleeding risk prediction score, including only 3 clinical factors for 
patients at high risk of developing hemorrhagic complications at OAC inception, however this level of 
simplicity may miss other important features that could put patients at risk of bleeding.  
Two bleeding risk scores, HEMORR2HAGES
8
 and the ABC bleeding score,
4
 included factors that 
are not routinely available in daily clinical practice. HEMORR2HAGES included genetic testing, although 
this was not available in their cohort, and the ABC score included 2 biomarkers, GDF-15 and cTnT-hs.  
The mean/median age of study population in the derivation cohort ranged from 61
15
 to 80.2 years
8
 
(Table 2). Almost half of the population in the derivation studies were female and only 3 studies
5,6,15
 
reported ethnicity, which was predominantly White.  Five out of 6
4-7,9
 studies from the AF cohorts reported 
hypertension as the most common co-morbid disease present in their population whereas one study from a 
VTE cohort
10
 and the mixed cohort
15
 reported kidney disease to be more prevalent in their patient 
population.  
Table 3 presents the characteristics of derivation and validation studies of bleeding risk scores for 
AF and VTE. A prospective study design was used in 3
4,5,7
 out of 6 scores for AF populations and 2
10,11
 out 
of 3 studies in VTE populations. Two
6,9
 studies used a retrospective analysis and 1 study
8
 derived their 
score from the previous bleeding score available in AF, while a retrospective study design was used in 1
12
 
VTE study and 1 mixed population study.
15
 
6 
 
Most studies in AF patients had follow-up for at least 1 year except the first score developed by 
Shiremen et al
9
 which followed their patients for the first 90 days following hospital discharge after AF 
diagnosis. In contrast, bleeding scores derived from VTE cohorts usually followed up patients for 3 months, 
as the duration of treatment of DVT/PE with warfarin is typically between 3-12 months depending on the 
type of VTE.
19
 All studies derived their risk score using bleeding risk factors from large cohorts of patients 
ranging from 3456
7
 to almost 20,000
9
 patients, apart from 2 studies, by Kuijer and Landefield et al. which 
only included 241 and 556 patients, respectively.
12,15
    
All bleeding risk scores stratified patients into 3 categories of bleeding risk (low, intermediate and 
high) except for the HAS-BLED score which initially categorised bleeding risk as high (score ≥3) and low-
moderate risk (0-2)
1
 and IMPROVE
10
 which categorized scores as ≥7 (increased risk of bleeding) and <7. 
These bleeding risk scores showed major bleeding rates ranging from 0.1%-3% in the low risk group and 
4.9%-30% in the high risk group in the validation cohorts. (Table 4)  
In terms of VTE prophylaxis, the most recent bleeding risk score developed to assess bleeding risks 
is the IMPROVE,
10
 and is perhaps the most comprehensive score by including more predictors of major 
bleeding (10 predictors), compared to the scores by Ruiz-Gimenez et al
11
 (6 predictors) and Kuijer et al
12
 (3 
predictors).  
The earliest bleeding score developed by Landefeld et al
15
 in 1989 derived 5 predictive factors of 
major bleeding in a mixed indication population. One of the original risk factors was AF but this was later 
removed when the score was validated, as its association with major bleeding was no longer significant in 
the validation cohort.  Diabetes mellitus was substituted instead of AF as a new predictor of major bleeding.  
The ability of the bleeding risk scores to predict bleeding risk has been validated both in cohorts to 
similar to ones where the score was derived (4 studies)
6,7,9,11
 and in independent validation cohorts (6 
studies).
4,5,8,10,12,20
 In the validation and comparison study by Hijazi et al,
4
  the ABC score statistically 
outperformed the HAS-BLED and ORBIT scores in predicting major bleeding in both the derivation cohort 
7 
 
[0·68 (95% CI 0·66–0·70) vs. 0·61 (0·59–0·63) vs. 0·65 (0·62–0·67), respectively; ABC-bleeding vs. 
HAS-BLED p<0·0001 and ABC-bleeding vs. ORBIT p=0·0008] and the external validation cohort [0·71 
(95% CI 0·68–0·73) vs. 0·62 (0·59–0·64) for HAS-BLED vs. 0·68 (0·65–0·70) for ORBIT; ABC-bleeding 
vs. HAS-BLED p<0·0001 and ABC-bleeding vs. ORBIT p=0·0016].
4
 Although the ABC score performed 
better than the HAS-BLED and ORBIT scores in this report, the complexity of the algorithm and inclusion 
of biomarkers which are not routinely performed in daily clinical practice, may make it difficult and more 
costly, for physicians to apply routinely.  
One recent meta-analysis
21
 compared the diagnostic accuracy between HAS-BLED and 
HEMORR2HAGES, ATRIA, CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with AF. The 
findings revealed that the HAS-BLED score performed better than the HEMORR2HAGES and ATRIA 
bleeding scores, as well as being superior to CHADS2 or CHA2DS2-VASc in predicting bleeding.  Despite 
having better performance when compared to HEMORR2HAGES, ATRIA and ORBIT, an additional 
advantage of the HAS-BLED score over the other five bleeding scores is the inclusion of quality of 
anticoagulation control (the ‘L’ acronym for labile INR or poor TTR<65%). Time in therapeutic (TTR) is a 
reflection of anticoagulation control in patients taking a VKA; a target TTR of ≥70% is optimal for efficacy 
and safety.
22
  
In a post-hoc analysis evaluating the performance of HAS-BLED, ATRIA and ORBIT bleeding 
risk scores in the AMADEUS trial,
23
 TTR was strongly correlated with clinically relevant bleeding events 
in patients using the ATRIA and ORBIT score, thus demonstrating that incorporating TTR in bleeding 
scores improves their ability to predict future bleeding events.  Another comparison of four bleeding risk 
scores (HAS-BLED, ORBIT, ATRIA and HEMORR2HAGES) in the SPORTIF cohort
24
  also investigated 
whether the addition of  ‘labile INR’ (TTR<65%) improved bleeding risk prediction (with the exception of 
the HAS-BLED score which already contains labile INR). Addition of  ‘labile INR’ to the ORBIT, ATRIA 
and HEMORR2HAGES bleeding risk scores, significantly improved the predictive performance of each 
8 
 
score for major bleeding [integrated discriminatory improvement (IDI) 0.0023, p=0.0092 vs. IDI 0.0020, 
p=0.00014 vs. IDI 0.0015, p=0.0016, respectively].
24
 
Apostolakis et al
25
 compared the predictive performance of HAS-BLED with HEMORR2HAGES 
and ATRIA in the AMADEUS trial and demonstrated that the HAS-BLED score performed better than 
HEMORR2HAGES and ATRIA score in predicting any clinically relevant bleeding, with only the HAS-
BLED score demonstrating significant improvement for intracranial hemorrhage.
25
 In another ancillary 
analysis of the same trial,
26
 the HAS-BLED score performed better than the ORBIT score in predicting any 
clinically relevant bleed in a non-oral anticoagulant (idraparinux).
26
 
More recently the predictive ability of the HAS-BLED score was also investigated in patients 
receiving NOAC therapy, with rivaroxaban, in a small retrospective case-control study;
27
 the HAS-BLED 
score demonstrated modest diagnostic ability to predict major bleeding events although this was not  
statistically significant (c statistics=0.68; p=0.07).
27
 Analyses have demonstrated that the HAS-BLED score 
not only performs well in predicting bleeding events in VKA treated patients with AF, it can also be used to 
predict bleeding events in non-VKA treated patients which is very useful as more AF patients are being 
treated with NOACs. 
27
 
Whereas in the VTE cohorts, only the IMPROVE score has been shown to have good predictive 
ability for major [ROC 0.67 (95% CI, 0.57-0.77; p=0.008)] and clinically important bleeding [ROC 0.64 
(95CI, 0.55-0.73; p=0.0080] at 14 days when validated by Hostler et al in a cohort of 1688 hospitalised 
patients.
28 
In conclusion, balancing individual risk of thromboembolic events and bleeding is complex but 
maximising the benefit of OAC while minimising bleeding risk, resulting in a net clinical benefit, should be 
undertaken in all patients receiving OAC. As reviewed here, there are many clinical prediction tools to 
assess bleeding risk prior to starting OAC for either stroke prevention in AF or treatment of VTE, which 
should be used in clinical practice to identify and manage modifiable risk factors. 
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Table 1: Risk factors for bleeding included in each bleeding risk score 
Risk factor ABC
4
 ORBIT
5
  
ATRIA
6
  
HAS-
BLED 
7
 
HEMORR2HA
GES 
8
  
Shireman 
9
  IMPROVE
10
  
Ruiz-
Gimenez 
11
  
Kuijer
12
 
OBRI 
15
 
 
Age ≥85           
Age≥75           
Age≥70           
Age≥65           
Age ≥60           
Age≥50           
Biomarkers           
Previous/remote 
bleed 
          
Recent bleed           
Anaemia           
Renal disease           
Liver disease           
Hypertension           
Myocardial 
infarction 
          
Diabetes           
Malignancy           
Stroke           
Combined 
antiplatelet therapy 
          
Labile INR           
Alcohol excess           
Excessive fall risk           
Genetic factors           
16 
 
Active gastro- 
duodenal ulcer 
          
Bleeding 3 months 
before admission 
          
Reduced platelet 
count 
          
ICU/CCU           
Central venous 
catheter 
          
Rheumatic disease           
Male sex           
Female sex           
Clinically overt 
PE 
          
Total no. of risk 
factors/score 
3 5 5 9 12 8 10 6 3 7 
CCU = coronary care unit; ICU = intensive coronary care unit; INR = international normalised ratio; PE = pulmonary embolism 
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Table 2: Baseline patient characteristics of the derivation cohorts for each bleeding risk score 
CAD = coronary artery disease; CHF = congestive heart failure; eGFR = estimated glomerular filtration rate; GI = gastrointestinal; Hb = hemoglobin; Hct = 
hematocrit; IQR = interquartile range; MI = myocardial infarction; NOACs = non-vitamin K antagonist oral anticoagulant; SD = standard deviation *anticoagulant 
discontinued; 
†population experiencing major bleed only; ‡ warfarin users only; §major bleed; || renal failure; ¶<30ml/min; #hepatic/renal failure; **CAD;  -  not 
reported 
 
Patients, % ABC
4
 
 
ORBIT
5
†  ATRIA
6
† 
 
HAS-
BLED
7
†  
HEMORR2
HAGES
8
‡
 
 
Shireman
9
 
 
IMPROVE
10
 Ruiz-
Gimenez
11
 
Kuijer
12
 OBRI
15
  
Number of 
patients  
14,537 581 307 53 1604 19,875 10,866 314 241 556 
Mean age 
(SD)/median 
(IQR) 
70  
(19-97) 
78  
(71–83) 
- 73 (10) 80.2 88%  
≥70 years 
68.1 
(51.8-78.9) 
 
66 (17) 63 (17) 61 (14) 
Sex (female) 36 46.1 37.4 53 57 52.5 50.6 45 46 54 
Ethnicity 
White 
- 91.6 86.2 - - - - - - 93 
History/ 
diagnosis of 
cancer 
- 30.8 18.0 - 4.8 2.5 10.7 35 24 - 
Anaemia/abnor
mal Hb/Hct 
- 57.5 18.8 - 8.5 7.5 - 56 - - 
Hypertension  87 89.3 64.7 74 0.4 72 38.7 - - - 
Diabetes  25 33.7 22.1 23 - 29.6 - - - 8 
CHF 31 44.9 - 45 - 59.8 10.8 7.6 - - 
MI 13 20.5 0.5 29
**
 - 68.5
**
 13 - - 4 
Prior stroke 19 13.1 17.4 12 37.2 32.1 - - - 12 
GI bleed - 15.5 12.1 17
§
 - 11.9 - 5.4 - 10 
eGFR 60ml/min 74.1 
ml/min 
48.4 5.9 
¶
 19
||
 - 0.6 
#
 
 
11.0
¶
 - - 18 
Antiplatelet  - 49.1 0.9 - - 22.3 24.6 14 - - 
Warfarin  - 95 - - 42.3 28.7 1.3* - - - 
NOACs - 5.2 - - - - - - - - 
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Table 3: Characteristics of the derivation and validation cohorts for each of the bleeding risk scores 
   Derivation cohort Validation cohort   
Risk score Year Country Indication 
for OAC 
Study design Subjects Follow-
up 
Indication 
for OAC 
Study design Subjects Follow-
up 
Major bleed 
definition 
 
ABC
4
 2016 Sweden AF Prospective 14,537 1.7 
years† 
AF Prospective 8468 1.9† ISTH  
ORBIT
5
 2015 USA AF Prospective 7411 2 years AF Prospective 14,264 1.9† ISTH  
ATRIA
6
 2011 USA AF Retrospective 6123 6 years AF Retrospective 3063 6 years ISTH  
HAS-BLED
7
 2010 Europe AF Prospective 3456 1 year AF Prospective 3071 1 year ISTH  
HEMORR2HAGES
8
 2006 USA     AF Retrospective 3791 3 years Hospitalisation 
for bleeding 
 
Shireman
9
 2006 USA AF Retrospective 19,875 3 mth AF Retrospective 6470 3 mth Hospitalisation 
for GI bleed or 
ICH 
 
IMPROVE
10,28
 2011 USA VTE Retrospective 
or 
prospective 
10,866 3 mth VTE Prospective 1668 18 mth ISTH  
Ruiz-Gimenez
11
 2008 Spain VTE Prospective 13,057 3 mth VTE Prospective 6572 3 mth ISTH  
Kuijer
12
 1999 The 
Netherlands 
VTE Retrospective 241 3 mth VTE Retrospective 780 3 mth ISTH  
OBRI
15,20
 1989 USA Mixed‡ Retrospective 556 48 mth Mixed‡ Prospective 264 48 mth ISTH  
             
AF = atrial fibrillation; DVT = deep vein thrombosis; GI = gastrointestinal; ICH = intracranial haemorrhage; ISTH = International Society of Thrombosis and 
Haemostasis; mth = months; PE = pulmonary embolism; TE = thromboembolism; TIA = transient ischaemic attack; VHD = valvalur heart disease; VTE = venous 
thromboembolism, valvular heart surgery, mitral valve disease, AF, stroke, transient ischemic attack (TIA), pulmonary embolism (PE), deep vein thrombosis 
(DVT), and other thromboembolism 
†median; ‡mixed indication included valvular heart disease, AF, stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other 
thromboembolism 
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Table 4: Risk factors, risk categories and bleeding events in the validation cohorts 
 
 
 
Risk score 
 
 
 
Risk factors (score for each factor) 
 
Risk categories 
Bleeding events in validation cohort 
(per 100 patient yrs) 
 
Low 
 
Intermediate 
 
High 
 
Low 
 
Intermediate 
 
High 
ABC
4
 Age(†); Biomarkers (†) (GDF-15 or cystatin C/CKD-EPI, cTnT-hs, & Hb); 
Previous bleed (†) 
<1% 1-2% >3% 0.62 1.67 4.87 
ORBIT
5
 Age ≥75 yrs (1); ↓Hb/Hct/anemia (2); Bleeding history (2); ↓ renal function 
(1); APT (1) 
0-2 3 ≥4 2.4* 4.7 8.1 
ATRIA
6
 Anemia (3); Severe renal disease (3); Age ≥75 yrs (2); Prior bleed (1); 
Hypertension (1) 
0-3 4 5-10 0.83 2.41 5.32 
HAS-BLED
7
 ↑SBP (1); Severe renal/hepatic disease (1 each); Stroke (1);Bleeding (1); Labile 
INR (1); Age >65 yrs (1); APT/NSAIDs (1); Alcohol excess (1) 
0-1 2 ≥3 1.02-1.13 1.88 ≥3.74 
HEMORR2HAGES
8
 Hepatic/renal disease (1); Ethanol abuse (1); Malignancy; Age >75 yrs (1); ↓Plt 
(1); Re-bleeding risk (2); ↑BP (1); Anemia (1); Genetic factors (1); ↑ falls risk 
(1); Stroke (1) 
0-1 2-3 ≥4 1.9-2.5 5.3-8.4 10.4-12.3 
Shireman et al
9
 Age ≥70 years (0.49);  Female (0.31); Previous bleed (0.58); Recent bleed 
(0.62); Alcohol/drug abuse (0.71); DM (0.27); Anemia (0.86); APT (0.32) 
≤1.07 >1.07/ <2.19 ≥2.19 0.9% a 2.0% a 5.4% a 
IMPROVE
10,28
 Active GI ulcer (4.5); Recent bleed (4); ↓Plt (4); Age ≥75 yrs (3.5); 
Hepatic/renal failure (2.5 each); ICU/CCU admission (2.5); CV catheter (2); 
Rheumatic disease (2); current cancer (2); Male (1) 
<7 - ≥7 2.7%‡   6.5%‡  
Ruiz-Gimenez et al 
11
 
Recent major bleed (2); ↑Creat (1.5); Anemia (1.5); Cancer (1); PE (1); Age 
>75 yrs (1) 
0 1-4 >4 0.1%
a
 2.8%
 a
 6.2%
 a
 
Kuijer et al 
12
 Age≥60 yrs (1.6); Female (1.3); Malignancy (2.2) 0 1-3 >3 0.6% a 2% a 7% a  
OBRI 
15,20
 Age≥65 yrs (1); Previous stroke (1); Previous GI bleed (1); Recent MI/ 
anemia/DM/↑ creat (1) 
0 1-2 3-4 3%
 b
 8%
 b
 30%
 b
 
APT = antiplatelet therapy; BP = blood pressure; CCU = coronary care unit; creat = creatinine; cTnT-hs = Troponin T; CV = central venous; DM = diabetes mellitus; GDF-15 = 
growth differentiation factor-15; GI = gastrointestinal;  Hb = haemoglobin; Hct = hematocrit; ICU = intensive care unit; INR = international normalised ratio; MI = myocardial 
infarction; PE: pulmonary embolism; Plt = platelet count or function; SBP = systolic blood pressure; yrs = years 
* bleeding event in original derivation cohort; 
a
 at 3 months; 
b
 at 12 months; ↓ reduced/decreased; ↑ elevated/increased; † score for each variable in ABC score is based on a 
nonogram (see reference
4
); ‡ clinically important bleeding: sum of major bleed and clinically relevant non-major 
 
